Jiangsu Simcere Pharmaceutical Co., Ltd.

This study tests whether adding the experimental drug suvemcitug to standard chemotherapy (FTD/TPI) helps people with advanced colorectal cancer that no longer responds to other treatments live longer. About 464 participants will receive either suvemcitug plus chemotherapy or a p…

This early-phase trial tests a new drug called SIM0500 in 130 adults with multiple myeloma that has come back or stopped responding to standard treatments. The drug is designed to help the immune system attack cancer cells from three different angles. The main goals are to check …

This study tests a new drug combination (SIM0270 plus everolimus) against standard treatments for people with a certain type of advanced breast cancer (ER+/HER2-) that has worsened after prior therapy. About 460 participants will be randomly assigned to receive either the new com…

This study tests a new drug called SIM0610 in adults with advanced solid tumors (cancers that have spread). The main goals are to check safety and find the right dose. About 260 people with certain cancers like lung, colon, head and neck, or liver cancer can join. The study has t…

This early-stage study is testing a new drug, SIM0609, in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. About 232 participants will take part in this first-in-human trial.

This early-stage study tests a new drug, SIM0811, in 72 healthy Chinese adults to see if it is safe and how the body processes it. Participants receive a single dose of the drug or a placebo and are monitored for side effects. The study does not aim to treat any disease, but to g…

This early-stage study in 60 healthy Chinese adults checks how the drugs itraconazole, rifampin, and midazolam change the levels of a new medicine called SIM0270 in the body. Participants take SIM0270 alone and with each other drug to see if there are any interactions. The study …